Treatment of Lymph Node–Negative, Early-Stage HER2-Positive Breast Cancer

2016 ◽  
Vol 34 (6) ◽  
pp. 639-640 ◽  
Author(s):  
Arzu Oguz ◽  
Gul Sema Keskin ◽  
Dilsen Colak ◽  
Ozden Altundag ◽  
Zafer Akcali
2015 ◽  
Vol 372 (2) ◽  
pp. 134-141 ◽  
Author(s):  
Sara M. Tolaney ◽  
William T. Barry ◽  
Chau T. Dang ◽  
Denise A. Yardley ◽  
Beverly Moy ◽  
...  

2021 ◽  
Vol 22 (8) ◽  
pp. 1139-1150
Author(s):  
Rosie Bradley ◽  
Jeremy Braybrooke ◽  
Richard Gray ◽  
Robert Hills ◽  
Zulian Liu ◽  
...  

2019 ◽  
Vol 17 (1) ◽  
pp. 47-56 ◽  
Author(s):  
Zachary Veitch ◽  
Omar F. Khan ◽  
Derek Tilley ◽  
Domek Ribnikar ◽  
Xanthoula Kostaras ◽  
...  

2020 ◽  
Vol 20 (6) ◽  
pp. 503-510
Author(s):  
Haiping Lin ◽  
Hongjuan Zheng ◽  
Chenyang Ge ◽  
Qinghua Wang ◽  
Wanfen Tang ◽  
...  

2019 ◽  
Vol 12 (4) ◽  
pp. 312-314 ◽  
Author(s):  
Christoph Suppan ◽  
Marija Balic

Summary Early stage HER2-positive cancer outcomes have been substantially improved over the last two decades, but there is still some potential for improvement. Several studies on the preoperative/postoperative treatment of HER2-positive breast cancer were presented at the American Society of Clinical Oncology (ASCO) 2019 annual meeting.


Sign in / Sign up

Export Citation Format

Share Document